WeFund Ventures
WeFund Ventures is a venture capital firm established in 2017 and headquartered in Tallinn, Estonia, with an additional office in Berlin, Germany. The firm specializes in early-stage investments across various sectors, including agritech, fintech, blockchain, security, biotech, enterprise solutions, big data, augmented reality/virtual reality, and aerospace. WeFund Ventures operates an acceleration fund that provides financing to very early-stage projects, utilizing an efficient syndicate funding structure that enhances its ability to mobilize substantial resources quickly and flexibly. The firm aims to support promising projects and drive innovation in its targeted industries.
Payris is the First Global Wish Place – a mobile operation system where customers publish their wishes and businesses complete them. Using Payris, consumer can publish a wish, get connected to a supplier who can complete the wish, and get rewarded for making their wishes come true through the app. Vendors may use Payris to buy hot leads and data for research. The platform tackles and solves the problem of social networks collecting and exploiting user data for free – Payris rewards users for sharing their wishes and completing surveys.
A.D.A.M. (Advanced Development of Additive Manufacturing) is a biotech company that provides 3D-bioprinting services on demand. A.D.A.M. uses its proprietary 3D-printing technology and patented materials to manufacture bioresorbable and biodegradable patient-specific implants (primarily, bone implants). By designing and building an on-demand tissue manufacturing solution, we have been pioneering this technology as a service model to effectively address a complex problem. The business model will allow patients to have their tissue modelled – using the MRI/CAT scans stored on the digital platform – and, subsequently, 3D-printed and implanted in certified clinics. We reached our main achievement to date in August, as the FDA responded to our Q-Sub (Pre-Submission) confirming our 510(k) regulatory path eligibility. This response means that no human trials and required and a decrease in time to market from 5 years to 1.5-2 years. Additionally, we have been accepted to join Technology Incubation Program at University of Connecticut in Farmington, CT. We have just moved our main office there as TIP offers state of the art research facilities and resources to its member companies. Our intention is to complete the required animal studies there. Finally, we have secured our lead investor for the upcoming Series A round.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.